Addressing the need for increased adherence to multiple sclerosis therapy: Can delivery technology enhance patient motivation?

Expert Opinion on Drug Delivery

Volumn 6, Issue 9, 2009, Pages 995-1002

  Lugaresi, Alessandra ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Auto injector; Drug delivery; Multiple sclerosis; Self injection; Skin reaction; Treatment adherence

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; NONSTEROID ANTIINFLAMMATORY AGENT;

BLOOD TOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; INJECTION PISTOL; INJECTION SITE REACTION; LIPOATROPHY; LIVER TOXICITY; MULTIPLE SCLEROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; VASODILATATION;

DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PATIENT EDUCATION AS TOPIC; SEVERITY OF ILLNESS INDEX; TECHNOLOGY, PHARMACEUTICAL;

EID: 70249142877     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903134769     Document Type: Review

References (47)

1. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Med J Med 2008;10:225
2. WHO. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization; 2003 • This reference outlines the global scale of the problem of poor adherence to drugs.
3. Smith SR, Wahed AS, Kelley SS, et al. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007;41:1116-1123
4. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224 (Pubitemid 38579798)
5. Lee WC, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41 (Pubitemid 44148014)
6. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.pub3
7. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996;47:123-129 (Pubitemid 26243872)
8. Tremlett H, van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008;17:565-576 (Pubitemid 351982762)
9. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-576
10. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-554 •• Perhaps the definitive study on patterns of adherence to MS therapies. (Pubitemid 37025380)
11. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50 • This study shows that adverse events are an important driver of treatment discontinuation in the first months of treatment, whereas later, perceived lack of efficacy becomes more important. (Pubitemid 40259974)
12. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-309 (Pubitemid 40775187)
13. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59:131-135 (Pubitemid 351301255)
14. Al-Sabbagh A, Bennet R, Kozma C, et al. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008;255(Suppl 2):S79 •• So far, this is the only study that shows that gaps in therapy with first-line MS treatment results in poorer outcomes.
15. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008;255(Suppl 6):87-92
16. Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009;23:453-462
17. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006;38:167-171
18. Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-132 (Pubitemid 32488430)
19. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996;2:222-226 (Pubitemid 126701610)
20. Avonex SPC. Available from: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/avonex/H-102-PI-en.pdf [Last accessed 14 July 2009]
21. Betaferon SPC. Available from: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/Betaferon/H-081-PI-en.pdf [Last accessed 14 July 2009]
22. Rebif SPC. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Rebif/H-136-PI-en.pdf [Last accessed 14 July 2009]
23. Copaxone SPC. Available from: http://emc.medicines.org.uk/medicine/17516/ SPC/Copaxone 20mg/ml, Solution For Injection, Pre-Filled Syringe/ [Last accessed 14 July 2009]
24. Edgar CM, Brunet DG, Fenton P, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63 (Pubitemid 38325760)
25. Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 2000;22:149-159 (Pubitemid 30072059)
26. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif ) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:585-591 • This study shows the main rationale for the use of auto-injectors for MS therapy. (Pubitemid 41387705)
27. Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices 1. Rev Neurol (Paris) 2006;162:735-740 • This study shows the main rationale for the use of auto-injectors for MS therapy. (Pubitemid 44046655)
28. Treadaway K, Cutter G, Lynch S, et al. A multivariate analysis of factors that influence adherence with disease-modifying therapy in multiple sclerosis. Mult Scler 2008;14:S182
29. Patti F, Amato MP, Bastianello S, et al. Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing - remitting multiple sclerosis: 2-year results from the COGIMUS study. Ther Adv Neurol Dis 2009;2:67-77
30. Flechter S, Vardi J, Finkelstein Y, et al. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J 2007;9:457-459 (Pubitemid 46979149)
31. Zivadinov R, Munschauer FE, Ramanathan M, et al. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon beta-1a in patients with MS and CIS. Drugs Today 2008;44:601-613
32. Montalban X, Rio J. Interferons and cognition. J Neurol Sci 2006;245:137-140
33. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol 2009;256:554-562
34. Kopke S, Kasper J, Muhlhauser I, et al. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult Scler 2008;15:96-104
35. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-236 (Pubitemid 34810404)
36. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new formulation of interferon {beta}-1a (Rebif(R) new formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009;15:219-228
37. Phillips JT, Rice G, Frohman E, et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004;26:511-521 (Pubitemid 38586452)
38. Lugaresi A, Durastanti V, Gasperini C, et al. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Clin Neuropharmacol 2008;31:167-172 (Pubitemid 351787112)
39. Jaber A, Bozzato GB, Vedrine L, et al. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol 2008;8:38
40. Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006;113:156-162
41. Lavery SA, El-Shawarby SA, Turner C, et al. The J-tip needle-free injection system in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study. Fertil Steril 2008;90:1969-1972
42. Porter R, Kissel C, Saunders H, et al. Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. Curr Med Res Opin 2008;24:727-735
43. Desrosiers P, O'Brien F, Blethen S. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005;2(Suppl 3):327-331 (Pubitemid 40469491)
44. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725 (Pubitemid 44841979)
45. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-962 (Pubitemid 46986681)
46. Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007;23:133-146 (Pubitemid 46191679)
47. Pfutzner A, Reimer T, Hohberg C, et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008;24:2545-2549